bacitracin; polymyxin b sulfate - Profile

What are the generic sources for bacitracin; polymyxin b sulfate and what is the scope of freedom to operate?

Bacitracin; polymyxin b sulfate is the generic ingredient in one branded drug marketed by Combe and is included in one NDA. Additional information is available in the individual branded drug profile pages.

Summary for bacitracin; polymyxin b sulfate

US Patents:	0
Tradenames:	1
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for bacitracin; polymyxin b sulfate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Combe	LANABIOTIC	bacitracin; polymyxin b sulfate	DISC;TOPICAL	050598-001	Sep 22, 1986		DISCN	No	No

Bacitracin and Polymyxin B Sulfate: Investment Outlook and Fundamental Analysis

Last updated: February 19, 2026

This analysis assesses the investment landscape for bacitracin and polymyxin B sulfate, focusing on their therapeutic roles, market dynamics, and patent expirations. Both are polypeptide antibiotics with established roles, primarily in topical applications, facing generic competition and limited new development.

What are the Core Therapeutic Applications of Bacitracin and Polymyxin B Sulfate?

Bacitracin is an antibiotic effective against gram-positive bacteria. Its primary clinical utility is in the treatment of superficial skin infections, such as impetigo, folliculitis, and infected minor cuts and abrasions. It is commonly formulated in ointments, creams, and ophthalmic preparations, often in combination with other antibiotics like neomycin and polymyxin B to broaden the spectrum of activity. Systemic bacitracin is rarely used due to nephrotoxicity and is reserved for life-threatening infections when other treatments are unavailable or ineffective.

Polymyxin B sulfate is a bactericidal antibiotic that targets gram-negative bacteria, particularly effective against Pseudomonas aeruginosa, Acinetobacter baumannii, and Enterobacteriaceae. Its application is largely limited to topical use for superficial infections of the eye, ear, and skin due to its significant nephrotoxicity and neurotoxicity upon systemic administration. It is also a component in combination topical preparations. Polymyxin B is utilized in irrigation solutions for surgical procedures to prevent gram-negative infections. The drug has seen a resurgence in interest for treating multidrug-resistant gram-negative infections, but this is primarily in the form of intravenous or inhaled administration, often as a last resort, and not directly related to the widely available topical formulations.

What is the Current Market Status and Competitive Landscape for These Antibiotics?

The market for bacitracin and polymyxin B sulfate is characterized by mature, genericized products. Both are off-patent and have been for decades, leading to widespread availability from multiple manufacturers at competitive prices.

Bacitracin is predominantly sold as a generic topical ointment, often in combination with other active ingredients. Major market players are typically generic pharmaceutical manufacturers. The demand is driven by over-the-counter (OTC) sales and prescription use for common skin infections. Competition is fierce, with pricing being a primary differentiator. Innovation in bacitracin products is minimal, focusing on formulation improvements for enhanced delivery or patient compliance rather than novel therapeutic applications.

Polymyxin B sulfate also exists primarily as a generic topical product. It is frequently found in combination ophthalmic and otic solutions and ointments. Similar to bacitracin, the market is populated by generic manufacturers, and price competition is substantial. While systemic polymyxin B is a critical drug for treating infections caused by highly resistant gram-negative bacteria, the market for these more advanced applications is distinct from the mass-market topical formulations. The development and supply chain for intravenous polymyxin B are subject to different pressures, including concerns about supply shortages and specialized manufacturing requirements.

What are the Key Patent Expirations and Their Implications?

Both bacitracin and polymyxin B are considered "old" antibiotics, and their original composition-of-matter patents expired many decades ago.

• Bacitracin: The original patents for bacitracin expired in the 1960s. Consequently, there are no active composition-of-matter patents protecting the core molecule. Any patent protection would likely be limited to specific formulations, manufacturing processes, or novel combination therapies that have been developed since. However, given the age of the drug and its established use, significant new patent filings for basic bacitracin are unlikely. The market is entirely generic.
• Polymyxin B Sulfate: Similar to bacitracin, the original patents for polymyxin B sulfate expired in the mid-20th century. No current composition-of-matter patents exist for the primary active ingredient. Patent activity related to polymyxin B might pertain to novel delivery systems, specific manufacturing techniques for improved purity or stability, or new therapeutic uses, particularly for multidrug-resistant infections. However, the vast majority of the market, especially topical formulations, operates in a post-patent environment.

The lack of patent protection for the core molecules means that market entry barriers are low for generic manufacturers. Pricing power is significantly diminished, and competition is driven by cost-efficiency in production and distribution. For investors, this translates to a market dominated by established, low-cost generics with limited opportunities for high-margin innovation based on the discovery of new chemical entities.

What is the Regulatory Status and Outlook for These Antibiotics?

The regulatory landscape for bacitracin and polymyxin B sulfate is well-established, given their long history of use.

• Bacitracin: Topical bacitracin products are widely approved by regulatory agencies like the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA). Many formulations are available over-the-counter (OTC), while others require a prescription. The regulatory focus is on established safety and efficacy profiles for their indicated uses. Any new formulations or combinations would undergo standard review processes. The rise of antibiotic resistance is a general concern for all antibiotics, but topical bacitracin's role in superficial infections limits its contribution to systemic resistance development compared to broad-spectrum oral or intravenous agents.
• Polymyxin B Sulfate: Topical polymyxin B sulfate products also have long-standing regulatory approvals for ophthalmic, otic, and dermatological uses. As with bacitracin, these are often available OTC or by prescription. The regulatory scrutiny for systemic polymyxin B, particularly for multidrug-resistant infections, is more intense. The FDA has implemented mechanisms like the U.S. Food and Drug Administration Safety and Innovation Act (FDASIA) to incentivize the development of novel antibiotics and address antimicrobial resistance, which could indirectly impact the supply and availability of drugs like polymyxin B for critical indications. However, this incentivization is not typically directed at revitalizing the market for older, generic topical formulations.

The established regulatory pathways for these antibiotics mean that the approval process for existing indications is relatively streamlined. However, the limited scope for novel therapeutic uses and the inherent risks associated with systemic polymyxin B present regulatory hurdles for new development in those areas.

What are the Economic and Market Considerations for Investors?

The economic profile of bacitracin and polymyxin B sulfate is that of mature, high-volume, low-margin products.

• Market Size and Growth: The global market for topical antibiotics is substantial but characterized by slow growth. Demand is steady due to the prevalence of common bacterial skin infections. However, the generic nature of bacitracin and polymyxin B means that market expansion is largely driven by volume increases rather than price appreciation. Growth is also tempered by the availability of alternative topical antibiotics and the increasing prevalence of antibiotic resistance, which can necessitate the use of newer, more expensive agents for certain infections.
• Profitability and Margins: Profitability for manufacturers is primarily derived from operational efficiency, economies of scale, and supply chain management. Margins on individual units are low due to intense price competition. Companies that can produce these antibiotics at the lowest cost are best positioned. The market is not conducive to significant research and development (R&D) investment for new blockbuster drugs based on these molecules.
• Investment Risks:
  • Intense Competition: The generic market is highly competitive, leading to price erosion.
  • Limited Differentiation: Opportunities for product differentiation are scarce, primarily limited to formulation or packaging.
  • Antibiotic Resistance: While less of a direct threat to topical use, the broader concern of antibiotic resistance can lead to shifts in treatment paradigms and increased use of reserve agents.
  • Supply Chain Vulnerabilities: As with many older generic drugs, the supply chain can be vulnerable to manufacturing disruptions or raw material shortages, impacting availability and potentially leading to price spikes for limited periods.
  • Lack of Innovation Pipeline: The absence of patent protection for the core molecules means there is little incentive for significant R&D investment by large pharmaceutical companies, limiting future growth prospects from novel applications.
• Investment Opportunities:
  • Generic Manufacturers: Companies with robust manufacturing capabilities and efficient supply chains for producing high-volume generic antibiotics can achieve profitability through scale.
  • Specialty Formulators: Companies focusing on improved topical formulations or combination products might find niche opportunities, but these require careful consideration of R&D costs versus potential market penetration.
  • Supply Chain Resilience: Investments in companies that ensure reliable supply of critical older antibiotics can be strategically valuable, particularly in the context of supply chain security concerns.

The investment case for bacitracin and polymyxin B sulfate rests on their established utility and broad use in dermatology and ophthalmology. However, the lack of patent exclusivity and the mature nature of these markets necessitate a focus on operational excellence and cost management rather than high-growth, innovation-driven strategies.

Key Takeaways

Bacitracin and polymyxin B sulfate are established polypeptide antibiotics with primary utility in topical applications for bacterial infections. Their original composition-of-matter patents expired decades ago, resulting in a market dominated by generic manufacturers. Competition is price-driven, and opportunities for significant innovation are limited. While demand is steady for treating common superficial infections, the economic outlook for investors is characterized by low margins and high volume. Companies with efficient manufacturing and strong supply chain management are best positioned to capitalize on this mature market. The resurgence of interest in polymyxin B for multidrug-resistant infections primarily concerns systemic administration, a distinct market from the widely available topical formulations.

Frequently Asked Questions

1. Are there any new therapeutic indications being explored for bacitracin or polymyxin B sulfate that could impact their market value? While systemic polymyxin B is being investigated for multidrug-resistant gram-negative infections, this is distinct from the established topical formulations of both antibiotics. For topical applications, significant new therapeutic indications are not actively being pursued due to their established roles and the availability of alternative agents.
2. What is the primary risk associated with investing in companies that solely focus on the manufacturing of generic bacitracin and polymyxin B sulfate? The primary risk is intense price competition within the generic pharmaceutical market, which can lead to persistent price erosion and squeezed profit margins. Operational efficiency and economies of scale become paramount for profitability.
3. Given the concerns about antibiotic resistance, is there a risk of these older antibiotics being phased out? For topical applications treating superficial infections, significant phasing out is unlikely in the short to medium term, as they remain cost-effective options for common pathogens. However, broader stewardship initiatives and the development of newer agents for more severe or resistant infections could gradually shift treatment paradigms.
4. Do any formulation patents currently protect specific bacitracin or polymyxin B sulfate products, and if so, what is their typical lifespan? While composition-of-matter patents have expired, patents may exist for specific novel formulations, delivery systems, or manufacturing processes. The lifespan of such patents typically follows standard patent terms, often up to 20 years from filing, but their impact on the broad generic market is usually limited.
5. How does the manufacturing complexity of polypeptide antibiotics like bacitracin and polymyxin B sulfate compare to small-molecule drugs, and how does this affect market entry? Polypeptide antibiotics often involve complex fermentation and purification processes, which can require specialized equipment and expertise. While this may present some technical barriers compared to the synthesis of simple small molecules, for established drugs like bacitracin and polymyxin B, numerous manufacturers have optimized these processes, lowering the effective barrier for generic entry.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Antibiotic Resistance. Retrieved from [FDA website] (specific URL not provided as it refers to a broad topic area, but represents agency information). [2] European Medicines Agency. (n.d.). Antimicrobials. Retrieved from [EMA website] (specific URL not provided as it refers to a broad topic area, but represents agency information). [3] National Institutes of Health. (n.d.). Polymyxin B. In LiverTox: Clinical and Translational Data. Retrieved from [NIH website] (specific URL not provided as it refers to a specific drug database entry). [4] Pharmaceutical industry reports and market analyses (various, often proprietary and not publicly cited in this format). [5] U.S. Food and Drug Administration. (2012). The U.S. Food and Drug Administration Safety and Innovation Act (FDASIA). Retrieved from [FDA website] (specific URL not provided as it refers to a specific act).